Sajid Khan
University of Florida
H-index: 20
North America-United States
Top articles of Sajid Khan
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies | Sajid Khan Vivekananda Budamagunta Daohong Zhou | 2023/1/1 | |
DDR-targeting small molecule inhibitor as a novel therapeutic for treating pancreatic ductal adenocarcinoma | Cancer Research | Trong Phat Do Sajid Khan Daohong Zhou Matthew Hart Stanton McHardy | 2023/4/4 |
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice | Cell Death Discovery | Sajid Khan Patrick Kellish Nick Connis Dinesh Thummuri Janet Wiegand | 2023/1/2 |
A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers | Cancer Research | Sajid Khan Janet Wiegand Peiyi Zhang Wanyi Hu Dinesh Thummuri | 2022/6/15 |
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers | Journal of Hematology & Oncology | Sajid Khan Janet Wiegand Peiyi Zhang Wanyi Hu Dinesh Thummuri | 2022/3/9 |
BCL-X | Sajid Khan Janet Wiegand Peiyi Zhang Wanyi Hu Dinesh Thummuri | 2022 | |
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216 | Molecular cancer therapeutics | Dinesh Thummuri Sajid Khan Patrick W Underwood Peiyi Zhang Janet Wiegand | 2022/1/1 |
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity | Nature communications | Dongwen Lv Pratik Pal Xingui Liu Yannan Jia Dinesh Thummuri | 2021/11/25 |
Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition | Journal of medicinal chemistry | Pratik Pal Dinesh Thummuri Dongwen Lv Xingui Liu Peiyi Zhang | 2021/9/17 |
DEGRADER OF BCL-2 PROTEIN FOR CANCER TREATMENT | 2021/6/9 | ||
BCL-2 Proteins Degraders for Cancer Treatment | 2021/3/25 | ||
Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells | Nature communications | Ryan Kolb Umasankar De Sajid Khan Yuewan Luo Myung-Chul Kim | 2021/2/24 |
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies | Yonghan He Sajid Khan Zhiguang Huo Dongwen Lv Xuan Zhang | 2020/12 | |
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity | Dinesh Thummuri Xingui Liu Wanyi Hu Peiyi Zhang Sajid Khan | 2020/4/15 | |
PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors | Peiyi Zhang Xuan Zhang Xingui Liu Sajid Khan Daohong Zhou | 2020 | |
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas | Journal of hematology & oncology | Yonghan He Raphael Koch Vivekananda Budamagunta Peiyi Zhang Xuan Zhang | 2020/12 |
Centchroman prevents metastatic colonization of breast cancer cells and disrupts angiogenesis via inhibition of RAC1/PAK1/β-catenin signaling axis | Life Sciences | Sajid Khan Samriddhi Shukla Mohammad Farhan Sonam Sinha Amar Deep Lakra | 2020/9/1 |
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics | Sajid Khan Yonghan He Xuan Zhang Yaxia Yuan Shaoyan Pu | 2020/6/25 | |
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity | Nature communications | Yonghan He Xuan Zhang Jianhui Chang Ha-Neui Kim Peiyi Zhang | 2020/4/24 |
Co-Authors
